Nicolas P
Unité du méningocoque, centre collaborateur OMS de référence et de recherche pour les méningocoques entre 1995 et 2011.
Med Sante Trop. 2012 Jul-Sep;22(3):246-58. doi: 10.1684/mst.2012.0086.
Group A meningococci are primarily responsible for the epidemic meningococcal diseases in the countries of the meningitis belt of sub-Saharan Africa. In 1995-1996 major epidemics (>200 000 cases) impeded effective management and ultimately resulted in many improvements. Since 2003, the Multi-Disease Center (MDSC) in Ouagadougou (Burkina Faso) and the WHO in Geneva have collected epidemiologic and laboratory data; new alert and epidemic thresholds are applied; and management has improved, with a single dose of ceftriaxone or of oily chloramphenicol now recommended. Trivalent ACW vaccine has been introduced against serogroup W135 epidemics. In 2010, preventive vaccination campaigns using the meningococcal conjugate vaccine MenAfriVac(®) began. Their use in all countries of the meningitis belt could eliminate serogroup A outbreaks in the region.
A群脑膜炎球菌是撒哈拉以南非洲脑膜炎带国家流行性脑膜炎球菌病的主要病因。1995年至1996年的主要疫情(超过20万例)阻碍了有效管理,最终促成了许多改进。自2003年以来,瓦加杜古(布基纳法索)的多疾病中心(MDSC)和日内瓦的世界卫生组织收集了流行病学和实验室数据;采用了新的警报和疫情阈值;管理得到了改善,现在推荐单剂量头孢曲松或油性氯霉素。已引入三价ACW疫苗以应对W135群疫情。2010年,开始使用脑膜炎球菌结合疫苗MenAfriVac®开展预防接种运动。在脑膜炎带所有国家使用该疫苗可消除该地区A群疫情。